Literature DB >> 30001523

Mechanisms of M. tuberculosis Immune Evasion as Challenges to TB Vaccine Design.

Joel D Ernst1.   

Abstract

Tuberculosis (TB) is a large global health problem, in part because of the long period of coevolution of the pathogen, Mycobacterium tuberculosis, and its human host. A major factor that sustains the global epidemic of TB is the lack of a sufficiently effective vaccine. While basic mechanisms of immunity that protect against TB have been identified, attempts to improve immunity to TB by vaccination have been disappointing. This Review discusses the mechanisms used by M. tuberculosis to evade innate and adaptive immunity and that likely limit the efficacy of vaccines developed to date. Despite multiple mechanisms of immune evasion, recent trials have indicated that effective TB vaccines remain an attainable goal. This Review discusses how knowledge from other systems can inform improvements on current vaccine approaches.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30001523      PMCID: PMC6482466          DOI: 10.1016/j.chom.2018.06.004

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  84 in total

1.  Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis.

Authors:  L C Rodrigues; V K Diwan; J G Wheeler
Journal:  Int J Epidemiol       Date:  1993-12       Impact factor: 7.196

Review 2.  Host evasion and exploitation schemes of Mycobacterium tuberculosis.

Authors:  C J Cambier; Stanley Falkow; Lalita Ramakrishnan
Journal:  Cell       Date:  2014-12-18       Impact factor: 41.582

3.  Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection.

Authors:  William W Reiley; Shahin Shafiani; Susan T Wittmer; Glady's Tucker-Heard; James J Moon; Marc K Jenkins; Kevin B Urdahl; Gary M Winslow; David L Woodland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-20       Impact factor: 11.205

4.  Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load.

Authors:  Cheryl L Day; Deborah A Abrahams; Lesedi Lerumo; Esme Janse van Rensburg; Lynnett Stone; Terrence O'rie; Bernadette Pienaar; Marwou de Kock; Gilla Kaplan; Hassan Mahomed; Keertan Dheda; Willem A Hanekom
Journal:  J Immunol       Date:  2011-07-20       Impact factor: 5.422

Review 5.  Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials.

Authors:  Punam Mangtani; Ibrahim Abubakar; Cono Ariti; Rebecca Beynon; Laura Pimpin; Paul E M Fine; Laura C Rodrigues; Peter G Smith; Marc Lipman; Penny F Whiting; Jonathan A Sterne
Journal:  Clin Infect Dis       Date:  2013-12-13       Impact factor: 9.079

6.  Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection.

Authors:  Nasiema Allie; Sergei I Grivennikov; Roanne Keeton; Nai-Jen Hsu; Marie-Laure Bourigault; Nathalie Court; Cecile Fremond; Vladimir Yeremeev; Yuriy Shebzukhov; Bernhard Ryffel; Sergei A Nedospasov; Valerie F J Quesniaux; Muazzam Jacobs
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

7.  Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis.

Authors:  M Cristina Gutierrez; Sylvain Brisse; Roland Brosch; Michel Fabre; Bahia Omaïs; Magali Marmiesse; Philip Supply; Veronique Vincent
Journal:  PLoS Pathog       Date:  2005-08-19       Impact factor: 6.823

8.  Mycobacterium tuberculosis induces the miR-33 locus to reprogram autophagy and host lipid metabolism.

Authors:  Mireille Ouimet; Stefan Koster; Erik Sakowski; Bhama Ramkhelawon; Coen van Solingen; Scott Oldebeken; Denuja Karunakaran; Cynthia Portal-Celhay; Frederick J Sheedy; Tathagat Dutta Ray; Katharine Cecchini; Philip D Zamore; Katey J Rayner; Yves L Marcel; Jennifer A Philips; Kathryn J Moore
Journal:  Nat Immunol       Date:  2016-04-18       Impact factor: 25.606

9.  Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.

Authors:  Birahim Pierre Ndiaye; Friedrich Thienemann; Martin Ota; Bernard S Landry; Makhtar Camara; Siry Dièye; Tandakha Ndiaye Dieye; Hanif Esmail; Rene Goliath; Kris Huygen; Vanessa January; Ibrahima Ndiaye; Tolu Oni; Michael Raine; Marta Romano; Iman Satti; Sharon Sutton; Aminata Thiam; Katalin A Wilkinson; Souleymane Mboup; Robert J Wilkinson; Helen McShane
Journal:  Lancet Respir Med       Date:  2015-02-26       Impact factor: 102.642

10.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.

Authors:  Michele D Tameris; Mark Hatherill; Bernard S Landry; Thomas J Scriba; Margaret Ann Snowden; Stephen Lockhart; Jacqueline E Shea; J Bruce McClain; Gregory D Hussey; Willem A Hanekom; Hassan Mahomed; Helen McShane
Journal:  Lancet       Date:  2013-03-23       Impact factor: 79.321

View more
  38 in total

1.  Tryptophan catabolism reflects disease activity in human tuberculosis.

Authors:  Jeffrey M Collins; Amnah Siddiqa; Dean P Jones; Ken Liu; Russell R Kempker; Azhar Nizam; N Sarita Shah; Nazir Ismail; Samuel G Ouma; Nestani Tukvadze; Shuzhao Li; Cheryl L Day; Jyothi Rengarajan; James Cm Brust; Neel R Gandhi; Joel D Ernst; Henry M Blumberg; Thomas R Ziegler
Journal:  JCI Insight       Date:  2020-05-21

Review 2.  Targeting innate immunity for tuberculosis vaccination.

Authors:  Shabaana A Khader; Maziar Divangahi; Willem Hanekom; Philip C Hill; Markus Maeurer; Karen W Makar; Katrin D Mayer-Barber; Musa M Mhlanga; Elisa Nemes; Larry S Schlesinger; Reinout van Crevel; Raman (Krishna) Vankayalapati; Ramnik J Xavier; Mihai G Netea
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

3.  Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.

Authors:  Zhidong Hu; Weimin Jiang; Ling Gu; Dan Qiao; Tsugumine Shu; Douglas B Lowrie; Shui-Hua Lu; Xiao-Yong Fan
Journal:  J Mol Med (Berl)       Date:  2019-11-30       Impact factor: 4.599

4.  Construction and Characterization of the Mycobacterium tuberculosis sigE fadD26 Unmarked Double Mutant as a Vaccine Candidate.

Authors:  Rogelio Hernandez-Pando; Sung Jae Shin; Simon Clark; Stefano Casonato; Martin Becerril-Zambrano; Hongmin Kim; Francesca Boldrin; Dulce Mata-Espinoza; Roberta Provvedi; Ainhoa Arbues; Brenda Marquina-Castillo; Laura Cioetto Mazzabò; Jorge Barrios-Payan; Carlos Martin; Sang-Nae Cho; Ann Williams; Riccardo Manganelli
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

Review 5.  Fighting Persistence: How Chronic Infections with Mycobacterium tuberculosis Evade T Cell-Mediated Clearance and New Strategies To Defeat Them.

Authors:  Laurisa Ankley; Sean Thomas; Andrew J Olive
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

Review 6.  Tuberculosis Vaccine Development: Progress in Clinical Evaluation.

Authors:  Suraj B Sable; James E Posey; Thomas J Scriba
Journal:  Clin Microbiol Rev       Date:  2019-10-30       Impact factor: 26.132

Review 7.  Moving tuberculosis vaccines from theory to practice.

Authors:  Peter Andersen; Thomas J Scriba
Journal:  Nat Rev Immunol       Date:  2019-09       Impact factor: 53.106

8.  TGFβ restricts expansion, survival, and function of T cells within the tuberculous granuloma.

Authors:  Benjamin H Gern; Kristin N Adams; Courtney R Plumlee; Caleb R Stoltzfus; Laila Shehata; Albanus O Moguche; Kathleen Busman-Sahay; Scott G Hansen; Michael K Axthelm; Louis J Picker; Jacob D Estes; Kevin B Urdahl; Michael Y Gerner
Journal:  Cell Host Microbe       Date:  2021-03-11       Impact factor: 21.023

9.  Expression of recombinant protease MarP from Mycobacterium tuberculosis in Pichia pastoris and its effect on human monocytes.

Authors:  Gerardo García-González; Jorge Ángel Ascacio-Martínez; Romel Hernández-Bello; Gloria María González; José Prisco Palma-Nicolás
Journal:  Biotechnol Lett       Date:  2021-05-24       Impact factor: 2.461

10.  In-host population dynamics of Mycobacterium tuberculosis complex during active disease.

Authors:  Roger Vargas; Luca Freschi; Maximillian Marin; L Elaine Epperson; Melissa Smith; Irina Oussenko; David Durbin; Michael Strong; Max Salfinger; Maha Reda Farhat
Journal:  Elife       Date:  2021-02-01       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.